SynthesisOncotarget2016
Clinicopathological and prognostic significance of regulatory T cells in patients with non-small cell lung cancer: A systematic review with meta-analysis.
Synthesis in Oncotarget, 2016. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 28 papers.
What it found
Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.
The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.
The trial behind it
Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.
Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.
Who cites it
28 citing papers in PubMed, 46 citations in OpenAlex.
- The paradoxical prognostic effects of T-cell-derived circulating DNA in EGFR-mutated advanced non-small-cell lung cancer involve the crosstalk between heme biosynthesis and immune microenvironment.Scientific reports · 2025Article
- A novel prediction model for the prognosis of non-small cell lung cancer with clinical routine laboratory indicators: a machine learning approach.BMC medical informatics and decision making · 2024Article
- Biomarkers for immunotherapy resistance in non-small cell lung cancer.Frontiers in oncology · 2024Review
- Cancer-associated fibroblast cell surface markers as potential biomarkers or therapeutic targets in lung cancer.Cancer drug resistance (Alhambra, Calif.) · 2024Review
- Immunoprofiling bronchoalveolar lavage cells reveals multifaceted smoking-associated immune dysfunction.ERJ open research · 2023Article
- Current literature review on the tumor immune micro-environment, its heterogeneity and future perspectives in treatment of advanced non-small cell lung cancer.Translational lung cancer research · 2023Review
- Prognostic and Predictive Biomarkers in the Era of Immunotherapy for Lung Cancer.International journal of molecular sciences · 2023Review
- A ferroptosis-related gene signature for overall survival prediction and immune infiltration in lung squamous cell carcinoma.Bioscience reports · 2022Article
- Emerging mechanisms progress of colorectal cancer liver metastasis.Frontiers in endocrinology · 2022Review
- The Colorectal Cancer Tumor Microenvironment and Its Impact on Liver and Lung Metastasis.Cancers · 2021Review
- Comparison of Tumor Microenvironments Between Primary Tumors and Brain Metastases in Patients With NSCLC.JTO clinical and research reports · 2021Article
- Overcoming microenvironmental resistance to PD-1 blockade in genetically engineered lung cancer models.Science translational medicine · 2021Article
- Regulatory T-Cells as an Emerging Barrier to Immune Checkpoint Inhibition in Lung Cancer.Frontiers in oncology · 2021Review
- Lung Microbiome Differentially Impacts Survival of Patients with Non-Small Cell Lung Cancer Depending on Tumor Stroma Phenotype.Biomedicines · 2020Article
- Melittin suppresses growth and induces apoptosis of non-small-cell lung cancer cells via down-regulation of TGF-β-mediated ERK signal pathway.Brazilian journal of medical and biological research = Revista brasileira de pesquisas medicas e biologica · 2020Article
- CD200 and CD200R1 are differentially expressed and have differential prognostic roles in non-small cell lung cancer.Oncoimmunology · 2020Article
- Infiltration of CD8International journal of clinical and experimental pathology · 2020Article
- Immune microenvironment composition in non-small cell lung cancer and its association with survival.Clinical & translational immunology · 2020Article
- Bevacizumab-Based Chemotherapy Triggers Immunological Effects in Responding Multi-Treated Recurrent Ovarian Cancer Patients by Favoring the Recruitment of Effector T Cell Subsets.Journal of clinical medicine · 2019Article
- High Aldehyde Dehydrogenase Levels Are Detectable in the Serum of Patients with Lung Cancer and May Be Exploited as Screening Biomarkers.Journal of oncology · 2019Article
Corrections and comments
PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.
Authors and funding
7 authors at 2 institutions in 1 country.
Funding
No grant is acknowledged in the PubMed record.
Abstract
The prognostic and clinicopathological value of regulatory T cells (Tregs) infiltration in patients with non-small cell lung cancer (NSCLC) remains undetermined. A comprehensive literature search of electronic databases (up to December 2015) was conducted. Relationship between Tregs infiltration and clinicopathological features, recurrence-free survival (RFS) and overall survival (OS) was investigated by synthesizing the qualified data. A total of 1303 NSCLC patients from 11 studies were included. The pooled hazard ratio (HR) for survival showed that high Tregs infiltration had no effect on RFS (HR = 2.03, 95% CI: 0.61-3.44, P = 0.708) and OS (HR = 1.20, 95% CI: 0.58-1.62, P = 0.981). High FoxP3+ Tregs infiltration was significantly associated with poor OS in NSCLC (HR = 3.88, 95% CI: 2.45-5.40, P = 0.000). Test methods, ethnicity and types of specimens had no effect on predicting prognosis of Tregs infiltration. While high Tregs infiltration was significantly correlated with smoking status [odds ratios (ORs) = 1.54, 95% CI: 1.15-2.08; P = 0.004], none of other clinicopathological characteristics such as gender, histological type, lymph node metastasis status, tumor size, vascular invasion, lymphatic invasion and pleural invasion were associated with Tregs infiltration. The present study demonstrated that high FoxP3+ Tregs infiltration was significantly associated with poor prognosis in NSCLC and smoking status.
Indexed as
Identifiers
What OpenQuestion holds
Registered trials
Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the OpenQuestion graph.